BOLERO3_2 | R Documentation |
Kaplan-Meier digitized data from BOLERO3, figure 2 (PMID 24742739). A reported sample size of 569 for a primary endpoint of PFS in breast cancer.
BOLERO3_2
A data frame of 569 observations and 3 variables:
time | event time (in weeks) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (eve_exe, placebo) | |
André F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 580–91.
summary(BOLERO3_2)
kmplot(BOLERO3_2)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.